-60%

est. 2Y upside i

Healthcare

Rank

#3388

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity upside is highly uncertain due to missing financial data (revenue, valuation, growth rate).

Last updated: July 3, 2026

Bull (20%)+10%

Commercial momentum accelerates with new country launches and regulatory approvals, sustaining a forward revenue multiple of 15x on projected $10.1M revenue, yielding ~$152M exit.

Base (35%)-50%

Gradual adoption with incumbent competition pressure compresses multiple to 8x, resulting in ~$81M exit, eroding valuation.

Bear (45%)-100%

Slow growth and strong incumbent response lead to sub-$109.6M exit, wiping out common equity due to preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

73%

Total funding of $109.6M likely exceeds common equity value in bear case, leaving common with zero recovery.

Dilution Risk

low

Recent debt financing and large total funding suggest no near-term equity raise needed.

Secondary Liquidity

none

No secondary market activity reported.

Questions to Ask at the Interview

Strategic questions based on Overture's data — designed to show you've done your homework.

  • 1

    “What is Overture's current annual recurring revenue and growth trajectory?”

  • 2

    “How does the company plan to compete against established players like CooperSurgical and Vitrolife?”

  • 3

    “What is the company's current valuation and what are the terms of the latest debt financing?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.